Brokerages Set Replimune Group, Inc. (NASDAQ:REPL) PT at $4.75

Shares of Replimune Group, Inc. (NASDAQ:REPL) have received an average recommendation of “Reduce” from the ten brokerages that are covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a sell rating and six have given a hold rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $4.75.

A number of brokerages have issued reports on REPL. Weiss Ratings raised Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 8th. Cantor Fitzgerald downgraded Replimune Group from an “overweight” rating to a “hold” rating in a report on Monday, April 13th. Wedbush reissued a “neutral” rating and issued a $2.00 price target (down from $19.00) on shares of Replimune Group in a report on Monday, April 13th. Piper Sandler downgraded Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 price target for the company. in a report on Friday, April 10th. Finally, Leerink Partners reissued a “market perform” rating and issued a $2.00 price target (down from $11.00) on shares of Replimune Group in a report on Monday, April 13th.

Replimune Group Trading Down 5.9%

Shares of NASDAQ:REPL opened at $4.91 on Friday. Replimune Group has a 12-month low of $1.50 and a 12-month high of $13.24. The company has a market capitalization of $405.42 million, a PE ratio of -1.43 and a beta of 0.12. The business has a 50 day moving average of $5.04 and a two-hundred day moving average of $7.37. The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33.

Insider Transactions at Replimune Group

In other Replimune Group news, insider Christopher Sarchi sold 6,500 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $8.01, for a total value of $52,065.00. Following the completion of the transaction, the insider directly owned 151,588 shares of the company’s stock, valued at approximately $1,214,219.88. The trade was a 4.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. International Assets Investment Management LLC acquired a new position in shares of Replimune Group during the 4th quarter worth approximately $29,000. Russell Investments Group Ltd. raised its stake in shares of Replimune Group by 3,638.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after buying an additional 7,569 shares during the period. CWM LLC raised its stake in shares of Replimune Group by 248.6% during the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after buying an additional 2,886 shares during the period. Essential Partners LLC raised its stake in shares of Replimune Group by 562,400.0% during the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after buying an additional 5,624 shares during the period. Finally, BNP Paribas Financial Markets raised its stake in shares of Replimune Group by 99.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock worth $58,000 after buying an additional 6,873 shares during the period. 92.53% of the stock is owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.